Oral Session 3-10B CML: Clinical Study (2)

[OS3-10B-1] The ELTS score clearly anticipates death due to CML and molecular response rates in CML-CP

Eriko Sato¹, Noriyoshi Iriyama², Michihide Tokuhira³, Tomoiku Takaku⁴, Maho Ishikawa⁵, Tomonori Nakazato⁶, Keiji Sugimoto⁷, Hiroyuki Fujita⁸, Yuta Kimura³, Isao Fujioka⁴, Norio Asou⁵, Norio Komatsu⁴, Masahiro Kizaki³, Yoshihiro Hatta², Tatsuya Kawaguchi^9,10 (1.Hematol., Juntendo Univ. Nerima Hosp., Tokyo, Japan, 2.Hematol and Rheumatol, Nihon University School of Medicine, Tokyo, Japan, 3.Hematol., Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4.Hematol., Juntendo University School of Medicine, Tokyo, Japan, 5.Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan, 6.Hematol, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 7.Hematol., Juntendo University Urayasu Hospital, Urayasu, Japan, 8.Hematol., Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan, 9.Hematol. and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan, 10.Kumamoto Health Science University, Kumamoto, Japan)